Industry Roundup: Prestige Brands CEO Change; P&G, Abbott, MJN Earnings
This article was originally published in The Tan Sheet
Executive Summary
Mannelly leaves, Lombardi moves up at Prestige; and Drug Facts mislabeling prompts RB recall.
You may also be interested in...
Slimmed-Down P&G To Consist Of 65 ‘Leading Brands’ By FY 2017
At the CAGNY conference Feb. 19, P&G leadership provided new insight into the company’s streamlining program, specifically where the firm will end up after selling off 100 underperforming brands in deals expected to be closed by June 30, 2016. CFO Jon Moeller listed Gillette, Pantene, Head & Shoulders and Olay among core brands that will emerge from the simplification, highlighting recent innovations and marketing initiatives that are resonating with its core audience and driving growth.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.